NCT04729725: Strategic Alliance: Phase 1b Trial Assessing Combination of TGF-β Inhibitor and PD-1 Inhibitor Cemiplimab

NCT04729725
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have previously received a PD-1 or PD-L1 inhibitor-based therapy & must have achieved stable disease (SD) for at least 6 months, or complete remission/partial remission (CR/PR) prior to disease progression (secondary resistance)
Exclusions: Patients with unstable, symptomatic, uncontrolled brain metastases or leptomeningeal disease- see trial for details; Patients with prior treatment with any anti-transforming growth factor beta (TGFb) inhibitors
https://ClinicalTrials.gov/show/NCT04729725

Comments are closed.

Up ↑